AstraZeneca (LON: AZN)‘s stock had its “buy” rating reaffirmed by investment analysts at Shore Capital Stockbrokers in a note issued to investors on Monday, Analyst Ratings.Net reports.
Shares of AstraZeneca (LON: AZN) opened at 3332.2881 on Monday. AstraZeneca has a one year low of GBX 2633.50 and a one year high of GBX 3544.50. The stock’s 50-day moving average is currently GBX 2919.40. The company’s market cap is £41.654 billion.
AZN has been the subject of a number of other recent research reports. Analysts at Galvan Research reiterated a “buy” rating on shares of AstraZeneca in a research note to investors on Monday. They now have a GBX 3,500 ($53.33) price target on the stock. Separately, analysts at UBS AG reiterated a “buy” rating on shares of AstraZeneca in a research note to investors on Friday. They now have a GBX 3,600 ($54.85) price target on the stock. Finally, analysts at AlphaValue reiterated a “reduce” rating on shares of AstraZeneca in a research note to investors on Wednesday, June 5th. They now have a GBX 3,371 ($51.36) price target on the stock.
Ten research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of GBX 4,154.91 ($63.31).
AstraZeneca PLC (LON: AZN) is a global biopharmaceutical company.